Annual Accounts Payable
$28.04 M
+$4.21 M+17.67%
December 31, 2023
Summary
- As of February 7, 2025, MDGL annual accounts payable is $28.04 million, with the most recent change of +$4.21 million (+17.67%) on December 31, 2023.
- During the last 3 years, MDGL annual accounts payable has risen by +$27.02 million (+2657.23%).
- MDGL annual accounts payable is now at all-time high.
Performance
MDGL Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$45.97 M
+$36.97 M+411.07%
September 30, 2024
Summary
- As of February 7, 2025, MDGL quarterly accounts payable is $45.97 million, with the most recent change of +$36.97 million (+411.07%) on September 30, 2024.
- Over the past year, MDGL quarterly accounts payable has increased by +$36.97 million (+411.07%).
- MDGL quarterly accounts payable is now at all-time high.
Performance
MDGL Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
MDGL Accounts Payable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +17.7% | +411.1% |
3 y3 years | +2657.2% | +411.1% |
5 y5 years | +1027.5% | +411.1% |
MDGL Accounts Payable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +31.2% | at high | +411.1% |
5 y | 5-year | at high | +2657.2% | at high | +4419.8% |
alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Madrigal Pharmaceuticals Accounts Payable History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $45.97 M(+411.1%) |
Jun 2024 | - | $8.99 M(-58.2%) |
Mar 2024 | - | $21.53 M(-23.2%) |
Dec 2023 | $28.04 M(+17.7%) | $28.04 M(+69.5%) |
Sep 2023 | - | $16.54 M(-5.7%) |
Jun 2023 | - | $17.53 M(+44.6%) |
Mar 2023 | - | $12.13 M(-49.1%) |
Dec 2022 | $23.83 M(+11.5%) | $23.83 M(+28.4%) |
Sep 2022 | - | $18.56 M(+64.4%) |
Jun 2022 | - | $11.29 M(-50.4%) |
Mar 2022 | - | $22.78 M(+6.5%) |
Dec 2021 | $21.38 M(+2002.3%) | $21.38 M(+105.2%) |
Sep 2021 | - | $10.42 M(+876.4%) |
Jun 2021 | - | $1.07 M(-75.7%) |
Mar 2021 | - | $4.40 M(+332.3%) |
Dec 2020 | $1.02 M(-13.7%) | $1.02 M(-83.8%) |
Sep 2020 | - | $6.28 M(+25.4%) |
Jun 2020 | - | $5.00 M(+348.8%) |
Mar 2020 | - | $1.11 M(-5.3%) |
Dec 2019 | $1.18 M(-52.6%) | $1.18 M(+52.4%) |
Sep 2019 | - | $773.00 K(+73.3%) |
Jun 2019 | - | $446.00 K(-89.8%) |
Mar 2019 | - | $4.38 M(+76.0%) |
Dec 2018 | $2.49 M(+28.9%) | $2.49 M(+141.2%) |
Sep 2018 | - | $1.03 M(+75.3%) |
Jun 2018 | - | $588.00 K(-58.6%) |
Mar 2018 | - | $1.42 M(-26.4%) |
Dec 2017 | $1.93 M(+153.1%) | $1.93 M(+37.8%) |
Sep 2017 | - | $1.40 M(+8.9%) |
Jun 2017 | - | $1.28 M(-53.8%) |
Mar 2017 | - | $2.78 M(+264.8%) |
Dec 2016 | $762.00 K(+644.9%) | $762.00 K(-34.3%) |
Sep 2016 | - | $1.16 M(+70.6%) |
Jun 2016 | - | $680.00 K(-8.6%) |
Mar 2016 | - | $744.00 K(+627.3%) |
Dec 2015 | $102.30 K | $102.30 K(-92.8%) |
Sep 2015 | - | $1.42 M(-52.8%) |
Jun 2015 | - | $3.02 M(-19.3%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2015 | - | $3.74 M(+19.1%) |
Dec 2014 | $3.14 M(-52.4%) | $3.14 M(-29.3%) |
Sep 2014 | - | $4.44 M(-15.0%) |
Jun 2014 | - | $5.23 M(-10.1%) |
Mar 2014 | - | $5.81 M(-11.8%) |
Dec 2013 | $6.59 M(+16.4%) | $6.59 M(+15.7%) |
Sep 2013 | - | $5.69 M(+9.0%) |
Jun 2013 | - | $5.22 M(-8.7%) |
Mar 2013 | - | $5.72 M(+1.0%) |
Dec 2012 | $5.66 M(+63.3%) | $5.66 M(+53.4%) |
Sep 2012 | - | $3.69 M(+6.4%) |
Jun 2012 | - | $3.47 M(+14.1%) |
Mar 2012 | - | $3.04 M(-12.3%) |
Dec 2011 | $3.47 M(+80.1%) | $3.47 M(+18.7%) |
Sep 2011 | - | $2.92 M(+46.1%) |
Jun 2011 | - | $2.00 M(+18.2%) |
Mar 2011 | - | $1.69 M(-12.2%) |
Dec 2010 | $1.93 M(-51.4%) | $1.93 M(-19.6%) |
Sep 2010 | - | $2.39 M(+87.0%) |
Jun 2010 | - | $1.28 M(-12.4%) |
Mar 2010 | - | $1.46 M(-63.1%) |
Dec 2009 | $3.96 M(+18.8%) | $3.96 M(-12.8%) |
Sep 2009 | - | $4.54 M(-24.3%) |
Jun 2009 | - | $6.00 M(-43.5%) |
Mar 2009 | - | $10.62 M(+218.7%) |
Dec 2008 | $3.33 M(+33.9%) | $3.33 M(+66.6%) |
Sep 2008 | - | $2.00 M(+35.9%) |
Jun 2008 | - | $1.47 M(-67.5%) |
Mar 2008 | - | $4.53 M(+82.1%) |
Dec 2007 | $2.49 M(-5.5%) | $2.49 M(+26.3%) |
Sep 2007 | - | $1.97 M(-0.6%) |
Jun 2007 | - | $1.98 M(+8.7%) |
Mar 2007 | - | $1.82 M(-30.8%) |
Dec 2006 | $2.63 M(-21.7%) | $2.63 M(+48.1%) |
Sep 2006 | - | $1.78 M(-47.1%) |
Dec 2005 | $3.36 M(+16.5%) | $3.36 M(-17.2%) |
Mar 2005 | - | $4.06 M |
Dec 2004 | $2.88 M(+1280.4%) | - |
Dec 2003 | $209.00 K | - |
FAQ
- What is Madrigal Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual accounts payable year-on-year change?
- What is Madrigal Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly accounts payable year-on-year change?
What is Madrigal Pharmaceuticals annual accounts payable?
The current annual accounts payable of MDGL is $28.04 M
What is the all time high annual accounts payable for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual accounts payable is $28.04 M
What is Madrigal Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, MDGL annual accounts payable has changed by +$4.21 M (+17.67%)
What is Madrigal Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of MDGL is $45.97 M
What is the all time high quarterly accounts payable for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly accounts payable is $45.97 M
What is Madrigal Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, MDGL quarterly accounts payable has changed by +$36.97 M (+411.07%)